Barely Significant
← all excerpts

Early-Stage B-cells Predict Relapse After Rituximab Treatment in Patients With Membranous Nephropathy.

Kidney Int Rep · 2026 · PMC13022648 · PMID 41907818

Europe PMCDOI
1
hedged sentence
0.0500
closest p · 1.0× alpha
0.0500
boldest claim

The sentences

showed a trendP = 0.05actually significant
However, patients showed a trend toward higher levels of total B-cell (median 1.79% vs. 0.65%, P = 0.05) and double-negative B-cells (0.22% vs. 0.12%, P = 0.06) ( Supplementary Figure S2 ).

also in 39,255 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.